Dr Matulonis discusses the FDA approval of mirvetuximab soravtansine-gynx in folate receptor alpha–positive, platinum-resistant ovarian cancer, key efficacy and safety data from the SORAYA trial, and how further research can continue the momentum behind finding effective ovarian cancer treatments.

S8 Ep3: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S8 Ep3: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Sign up to save your podcasts

S8 Ep3: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

S8 Ep3: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

More shows like OncLive® On Air

Hematologic Oncology Update

Journal of Clinical Oncology (JCO) Podcast

Research To Practice | Oncology Videos

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

The New Yorker Radio Hour

ASCO Daily News

The Daily

OncoPharm

ASCO Guidelines

Lung Cancer Considered

Oncology Today with Dr Neil Love

CCO Oncology Podcast

The Ezra Klein Show

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions